from GenomeWeb by Monica Heger
NEW YORK (GenomeWeb) – Researchers from Massachusetts General Hospital have described a method behind two clinical cancer assays — a targeted RNA-seq fusion assay and a hotspot mutation assay — each of which the team has now used to assess more than 1,000 patients.
The method for both assays relies on anchored multiplex PCR (AMP) coupled with next-generation sequencing and was described recently in Nature Medicine.
Long Le, an assistant professor of pathology at MGH, told GenomeWeb that Enzymatics has commercialized the AMP technology. MGH had exclusively licensed the IP to startup ArcherDx, which Enzymatics subsequently purchased for $50 million last year.
(read more…)
from GenomeWeb by Monica Heger
NEW YORK (GenomeWeb) – Researchers from Massachusetts General Hospital have described a method behind two clinical cancer assays — a targeted RNA-seq fusion assay and a hotspot mutation assay — each of which the team has now used to assess more than 1,000 patients.
The method for both assays relies on anchored multiplex PCR (AMP) coupled with next-generation sequencing and was described recently in Nature Medicine.
Long Le, an assistant professor of pathology at MGH, told GenomeWeb that Enzymatics has commercialized the AMP technology. MGH had exclusively licensed the IP to startup ArcherDx, which Enzymatics subsequently purchased for $50 million last year.
(read more…)
Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
from GenomeWeb by Monica Heger
NEW YORK (GenomeWeb) – Researchers from Massachusetts General Hospital have described a method behind two clinical cancer assays — a targeted RNA-seq fusion assay and a hotspot mutation assay — each of which the team has now used to assess more than 1,000 patients.
The method for both assays relies on anchored multiplex PCR (AMP) coupled with next-generation sequencing and was described recently in Nature Medicine.
Long Le, an assistant professor of pathology at MGH, told GenomeWeb that Enzymatics has commercialized the AMP technology. MGH had exclusively licensed the IP to startup ArcherDx, which Enzymatics subsequently purchased for $50 million last year.
(read more…)
Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
Stay Connected
Submit a Post to the Blog
Recent Posts
Subscribe to the RNA-Seq Blog
RNA-Seq Products & Services